Key Points

Summit Partners divested 2,100,000 shares of Aveanna Healthcare during the first quarter, with the trade valued at roughly $16.23 million using quarterly average prices.
The fund's position value at quarter-end dropped by $26.62 million, accounting for the sale and stock price fluctuations.
This move marked a 2.42% shift in the fund's reportable assets under management.

On May 8, 2026, Summit Partners revealed in an SEC filing that it sold 2,100,000 shares of Aveanna Healthcare (NASDAQ:AVAH), a transaction estimated at $16.23 million based on average quarterly closing prices.

What Happened

Summit Partners' SEC filing from May 8, 2026, detailed the sale of 2,100,000 Aveanna Healthcare shares, totaling about $16.23 million at the quarter's average closing price. The fund's holding value fell by $26.62 million by quarter-end, influenced by both the divestment and market price changes.

What Else to Know

Summit Partners further trimmed its Aveanna Healthcare position, now comprising 5.23% of its 13F reportable assets under management post-sale.
Top holdings following the filing:
- NYSE:KVYO: $366.88 million (54.7% of AUM)
- NASDAQ:LFST: $186.07 million (27.8% of AUM)
- NYSE:AKA: $62.43 million (9.3% of AUM)
- NASDAQ:AVAH: $35.08 million (5.2% of AUM)
- NASDAQ:MTSI: $10.94 million (1.6% of AUM)
Aveanna Healthcare stock closed at $6.94 on May 7, 2026, reflecting a 23% gain over the previous year.

Company Overview

Metric	Value
Revenue (TTM)	$2.43 billion
Net Income (TTM)	$225.03 million
Price (as of market close May 7, 2026)	$6.94

Company Snapshot

Aveanna Healthcare delivers private duty nursing, home health and hospice services, pediatric therapy, and enteral nutrition, drawing revenue from Private Duty Services, Home Health & Hospice, and Medical Solutions segments.
The company runs a broad home care network that provides skilled nursing and therapy in patients' homes, cutting dependence on pricier institutional care.
It caters to medically fragile children, adults needing home care, and families pursuing pediatric or hospice options nationwide.

Aveanna Healthcare specializes in home-based medical services across the U.S., targeting complex pediatric and adult cases. Its patient-focused platform keeps care in homes and minimizes expensive facility use, operating a versatile home care business throughout the country.

What This Transaction Means for Investors

The divestment appears to be a measured step to lock in profits rather than a vote of no confidence in Aveanna's fundamentals. Summit Partners retains over 5% of its reported assets in the stock post-sale, and recent financials show no signs of trouble.

Aveanna recently delivered one of its best performances since its public debut. Annual revenue rose 20.2% to $2.43 billion, adjusted EBITDA jumped nearly 75% to $320.9 million. It produced $131 million in free cash flow in 2025 and closed the year with $193 million in cash reserves.

Looking ahead, expansion through acquisitions stands out, such as the upcoming $175.5 million Family First Homecare purchase set to finalize this quarter. Investors should monitor if leadership can convert this growth into sustained margin improvements and robust cash generation.